课题基金 / 基金详情

Acquisition and Selection of Antibiotic Resistance in Companion and Farmed Animals and Implications for Transmission to Humans

Acquisition and Selection of Antibiotic Resistance in Companion and Farmed Animals and Implications for Transmission to Humans
伴侣动物和养殖动物抗生素耐药性的获得和选择及其对人类传播的影响
批准号:
NE/N01961X/1
负责人:
Matthew Avison
金额:
$181.79万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2016
资助国家:
英国
项目状态:
已结题
起止时间:
2016 至 --

项目摘要

项目成果

Matthew Avison的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Without antimicrobial drugs, the risk of bacterial infection would render many common medical procedures too dangerous to contemplate because of the risk of infections caused by "opportunistic bacteria". They can live on the patient's skin, or in their intestines, and infection occurs when bacteria get into parts of the body that are normally sterile. A perfect example is urinary tract infection (UTI) caused by faecal bacteria. E. coli is particularly abundant in human faeces so is perfectly placed to cause opportunistic infections. It is one of the most common causes of healthcare pneumonia, surgical site infection, bloodstream infection and UTI in the UK. In order to prevent against and treat opportunistic infections, patients are given antimicrobials.Almost all antimicrobials are "antibiotics", which means they are derived from natural chemicals produced by microbes found in the environment. Natural antibiotics have been present in the environment for millions of years, and so bacteria living in their presence have had time to evolve mechanisms that can resist their actions, encoded by "resistance genes". Opportunistic bacteria like E. coli can randomly acquire these pre-evolved resistance genes and in a single step, they become insusceptible to a particular antimicrobial. If that insusceptible E. coli colonises a person and then causes an opportunistic infection, the infection will not be treatable with that particular antimicrobial. We refer to this as "antimicrobial resistance" (AMR); however AMR bacteria don't just resist clinical antimicrobial therapy, they beat it.Animals also carry an abundance of E. coli in their intestines and are frequently treated with antimicrobials. This can select for the acquisition of AMR E. coli which can then be passed on to another animals, directly, or via contamination of the environment with faeces. Theoretically, the AMR E. coli could also be passed on to people, and there is much debate about whether such "zoonotic transmission" happens to any significant degree. This is an important debate because it has led to calls from some to dramatically reduce the amount of antimicrobials that are given to animals with the view that it will reduce the level of AMR in animals, and so the possibility of zoonotic transmission to people. But the potential impact on welfare and food production means this should only be done if there is evidence that it will work.In this project we will identify what drives acquisition of AMR in animals using E. coli as the exemplar bacterium and dairy cows and dogs as exemplar farmed and companion animals. We will test whether AMR bacteria encountered by an animal as it interacts with the environment influence the AMR profile in its faeces, and/or whether early life antimicrobial use plays a part in selection of AMR bacteria in animals. We will also test whether reducing antimicrobial use in dairy cows actually does reduce AMR in the near-farm environment that is contaminated with their faeces. We will test whether exercising in these contaminated near-farm environments influences the abundance of AMR bacteria in dogs, and whether there is any evidence of direct acquisition of AMR E. coli by dogs from near-farm environments, which might be brought into the home.Finally, we will investigate whether AMR abundance in human UTI E. coli reduces as antimicrobial drug prescribing reduces in primary care; whether living close to a farm affects AMR abundance in UTI E. coli; whether there is direct evidence for E. coli carried by dogs or found in near-farm environments contaminated by cattle faeces also causing UTIs in humans.These interlaced studies will provide much needed data about the management changes that might reduce AMR in animals and in humans, and are designed to address the fundamental question of whether zoonotic transmission is particularly significant as a driver of AMR in people relative to antimicrobial drug use by doctors.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.onehlt.2021.100220
发表时间: 2021-06
期刊: One health (Amsterdam, Netherlands)
影响因子: --
作者: [Booton RD, Meeyai A, Alhusein N, Buller H, Feil E, Lambert H, Mongkolsuk S, Pitchforth E, Reyher KK, Sakcamduang W, Satayavivad J, Singer AC, Sringernyuang L, Thamlikitkul V, Vass L, OH-DART Study Group, Avison MB, Turner KME]
通讯作者: Turner KME
DOI: 10.1093/jac/dkx525
发表时间: 2018-05-01
期刊: The Journal of antimicrobial chemotherapy
影响因子: --
作者: [Bryce A, Costelloe C, Wootton M, Butler CC, Hay AD]
通讯作者: Hay AD
Molecular epidemiology of Escherichia coli producing CTX-M and plasmid AmpC-type ß-lactamases from dairy farms identifies a dominant plasmid encoding CTX-M-32 but no evidence for transmission to humans in the same geographical region
从奶牛场产生 CTX-M 和质粒 AmpC 型 β-内酰胺酶的大肠杆菌的分子流行病学鉴定出编码 CTX-M-32 的显性质粒,但没有证据表明在同一地理区域传播给人类
DOI: 10.1101/845917
发表时间: 2019
期刊:
影响因子: --
作者: [Findlay J]
通讯作者: Findlay J
Characterisation of AmpC Hyper-Producing Escherichia coli from Humans and Dairy Farms Collected in Parallel in the Same Geographical Region
从同一地理区域平行收集的人类和奶牛场中 AmpC 高产大肠杆菌的特征
DOI: 10.1101/784694
发表时间: 2019
期刊:
影响因子: --
作者: [Alzayn M]
通讯作者: Alzayn M
Canada_IPAP - Impacts of antibiotic usage reduction in farmed animals
  • 批准号:
    BB/X012670/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $19.35万
  • 财政年份:
    2023
  • 负责人:
    Matthew Avison
  • 依托单位:
One Health Drivers of Antibacterial Resistance in Thailand
  • 批准号:
    MR/S004769/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $371.96万
  • 财政年份:
    2018
  • 负责人:
    Matthew Avison
  • 依托单位:
One Health Drivers of Antibacterial Resistance in Thailand
  • 批准号:
    MR/R014922/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $9.02万
  • 财政年份:
    2017
  • 负责人:
    Matthew Avison
  • 依托单位:
Detecting Antibiotic Resistance Proteins in Clinical Samples Using Proteomics
  • 批准号:
    MR/N013646/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $24.95万
  • 财政年份:
    2016
  • 负责人:
    Matthew Avison
  • 依托单位:
国内基金
海外基金
Intelligent Patent Analysis for Optimized Technology Stack Selection:Blockchain BusinessRegistry Case Demonstration
  • 批准号:
    --
  • 项目类别:
    外国学者研究基金项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    USHARANI HAREESH GOVINDARA JAN
  • 依托单位:
连锁群选育法(Linkage Group Selection)在柔嫩艾美耳球虫表型相关基因研究中应用